The median age of Treg-treated patients was 62 (r:45-69), 5 were male, 6 had acute leukemia, 4 had CLL/lymphoma. The median infused combined nucleated and CD3+ cell doses of the UCB graft were 4 x10e7 (r:4-9) and 16.5 x 10e6 (r:14-18), respectively. None had a severe adverse event with the infusion. One Treg treated patient developed a skin rash on day +16; biopsy was equivocal for engraftment syndrome to be conservative we considered as aGVHD. Thus, the incidence of grade 2-4 aGVHD by day +100 was 10% (95% CI, 0-28%) as compared to 53% (95% CI, 27-79%) in the controls (p¼.04, Figure) . One patient developed grade 3 late gastrointestinal aGVHD in the Treg group (day 119). Engraftment was similar between Treg (90%, 95% CI, 74-99%) and control (87%, 95% CI, 65-98%) groups (p¼.92). The median follow-up is too short for assessment of chronic GVHD and relapse. In summary, we 1) demonstrated the ability to consistently manufacture Treg doses up to 100 x10 e6/kg which allows for Treg: T effector ratio of up to 7:1, and 2) observed a remarkably low risk of aGVHD. This promising result is the first clear demonstration that ex vivo expanded UCB Treg are potent suppressors of aGVHD in humans and sets the stage for a future pivotal clinical trial that will assess the clinical impact of Treg GVHD prophylaxis on immune recovery and risk of leukemia relapse.
The median age of Treg-treated patients was 62 (r:45-69), 5 were male, 6 had acute leukemia, 4 had CLL/lymphoma. The median infused combined nucleated and CD3+ cell doses of the UCB graft were 4 x10e7 (r:4-9) and 16.5 x 10e6 (r:14-18), respectively. None had a severe adverse event with the infusion. One Treg treated patient developed a skin rash on day +16; biopsy was equivocal for engraftment syndrome to be conservative we considered as aGVHD. Thus, the incidence of grade 2-4 aGVHD by day +100 was 10% (95% CI, 0-28%) as compared to 53% (95% CI, 27-79%) in the controls (p¼.04, Figure) . One patient developed grade 3 late gastrointestinal aGVHD in the Treg group (day 119). Engraftment was similar between Treg (90%, 95% CI, 74-99%) and control (87%, 95% CI, 65-98%) groups (p¼.92). The median follow-up is too short for assessment of chronic GVHD and relapse. In summary, we 1) demonstrated the ability to consistently manufacture Treg doses up to 100 x10 e6/kg which allows for Treg: T effector ratio of up to 7:1, and 2) observed a remarkably low risk of aGVHD. This promising result is the first clear demonstration that ex vivo expanded UCB Treg are potent suppressors of aGVHD in humans and sets the stage for a future pivotal clinical trial that will assess the clinical impact of Treg GVHD prophylaxis on immune recovery and risk of leukemia relapse. Graft versus host disease (GvHD) is the most common complication of hematopoietic stem cell transplant (HCT). However, our understanding of the molecular pathways that cause this disease remains incomplete, leading to inadequate targeted strategies for prevention and treatment. To address this, we determined the gene expression profile of non-human primate (NHP) T cells during active and partially controlled acute GvHD (aGvHD), in order to accomplish two goals: 1) uncover important genetic drivers of aGvHD and 2) identify novel, targetable pathways for optimal aGvHD prevention.
Utilizing microarray technology, we measured the gene expression profiles of flow cytometrically purified CD3+ T cells from NHP recipients of MHC partially matched HCT in three treatment cohorts resulting in increasing degrees of survival: 1) no immunoprophylaxis (No Rx, MST ¼ 7.5); 2) sirolimus monotherapy (MST ¼ 17; and 3) tacrolimus-methotrexate (tac-mtx) dual prophylaxis (MST ¼ 49). Arrays were performed on T cells purified on Day +14 post-transplant (unless terminal analysis occurred earlier due to severe disease). This comparison allowed us to determine the impact of both mTOR and calcineurin inhibition on the molecular pathways dysregulated during GvHD, and to determine which genes and pathways remained dysregulated despite prophylaxis. Pathways identified by this strategy may contain new therapeutic targets unaffected by current immunoprophylactic approaches. We found that the transcriptional profile of donor T cells from HCT recipients with unprophylaxed GvHD was characterized by significant perturbation of pathways regulating T cell proliferation, effector function and cytokine synthesis. By identifying pathways unaffected by sirolimus or tac-mtx therapy, we discovered multiple potentially druggable targets not previously implicated in the pathophysiology of aGvHD. These targets prominently included the hedgehog and the aurora kinase A pathways. Utilizing a murine aGvHD model, we demonstrated that pharmacologic inhibition of these pathways could mitigate disease and improve survival.
These data provide the first identification of the T cell transcriptome of primate acute GvHD and the hedgehog and aurora kinase A pathways as novel potential targets for prevention of this disease. aGVHD enrolled in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) trials 0302 (N¼105, serum) and 0802 (N¼158, plasma). Samples were analyzed at aGVHD onset and day 28 post-aGVHD treatment and compared to control samples obtained at day +100 from University of Minnesota allogeneic hematopoietic cell transplant (HCT) recipients without aGVHD (N¼53, serum).
Results: In the pilot study, significant differences in the levels of FS, EGF, VEGF-A, PlGF, Ang2, and sEng were found when comparing patients with aGVHD, allogeneic HCT recipients without aGVHD, and HD in the pilot study. In the CTN validation cohorts (Figure 1 ), VEGF-A and EGF were significantly lower in patients with aGVHD compared to HCT controls. FS, sEng, and PlGF were all significantly elevated in patients with aGVHD compared to controls. In multivariate analyses of 6-month survival including age, stage, and day 28 response in the validation cohorts, the day 28 FS level was an independent prognostic factor for survival in both CTN 0302 (HR 9.3, 95% CI 1.3e59.1, p¼0.002) and 0802 (HR 2.8, 95% CI 1.04e6.9, p¼0.04), with outcomes significantly worse when day 28 FS > 2000 pg/mL (Figure 2) . 
